Expert consensus to optimize the management of older adult patients with advanced EGFR-mutated non-small cell lung cancer
Lung cancer (LC) is associated with ageing, with the average age of affected individuals
being approximately 70 years. However, despite a higher incidence and prevalence among …
being approximately 70 years. However, despite a higher incidence and prevalence among …
Osimertinib early dose reduction as a risk to brain metastasis control in EGFR‐mutant non‐small cell lung cancer
T Tozuka, R Noro, A Miyanaga, S Nakamichi… - Cancer …, 2023 - Wiley Online Library
Background The epidermal growth factor receptor (EGFR) mutation is a risk factor
associated with brain metastases (BMs) in patients with non‐small cell lung cancer …
associated with brain metastases (BMs) in patients with non‐small cell lung cancer …
Prospective exosome-focused translational research for afatinib (EXTRA) study of patients with nonsmall cell lung cancer harboring EGFR mutation: an observational …
S Takata, K Morikawa, H Tanaka… - Therapeutic …, 2023 - journals.sagepub.com
Background: The exosome-focused translational research for afatinib (EXTRA) study is the
first trial to identify novel predictive biomarkers for longer treatment efficacy of afatinib in …
first trial to identify novel predictive biomarkers for longer treatment efficacy of afatinib in …
Real-World Treatment Outcomes and Safety of Afatinib in Advanced Squamous Cell Lung Cancer Progressed after Platinum-Based Doublet Chemotherapy and …
W Ji, IJ Oh, CK Park, SY Lee, J Choi, JC Lee, J Kim… - Cancers, 2023 - mdpi.com
Simple Summary Although the LUX-Lung 8 trial has demonstrated the clinical benefit of
afatinib as a second-line treatment for squamous cell carcinoma of the lung (LSCC), data on …
afatinib as a second-line treatment for squamous cell carcinoma of the lung (LSCC), data on …
Afatinib plus osimertinib in the treatment of osimertinib-resistant non-small cell lung carcinoma: a phase I clinical trial
S Miura, Y Koh, K Azuma, H Yoshioka, K Koyama… - BMC cancer, 2023 - Springer
Background Conquering acquired resistance to osimertinib remains a major challenge in
treating patients with epidermal growth factor receptor (EGFR) mutation-positive non-small …
treating patients with epidermal growth factor receptor (EGFR) mutation-positive non-small …
Alternating Therapy With Osimertinib and Afatinib Blockades EGFR Secondary Mutation in EGFR-Mutant Lung Cancer: A Single-Arm Phase II Trial
K Yonesaka, H Hayashi, A Nakamura, Y Sato… - Clinical Lung Cancer, 2023 - Elsevier
Background Resistance to epidermal growth factor receptor tyrosine kinase inhibitors (EGFR-
TKIs) has limited treatment options for patients with EGFR-mutated non–small-cell lung …
TKIs) has limited treatment options for patients with EGFR-mutated non–small-cell lung …
A Case of Binocular Metastatic Choroidal Tumor Originating from Pulmonary Adenocarcinoma Successfully Treated with Molecular Target Therapy
M Yamaoka, T Igarashi, N Shiratori… - Case Reports in …, 2023 - karger.com
The occurrence of ocular metastasis from lung cancer is uncommon. In our current case, we
report on a 64-year-old male patient found to have metastatic lesions in both choroids after …
report on a 64-year-old male patient found to have metastatic lesions in both choroids after …
[引用][C] Clinical phase II trial shows that combining osimertinib and afatinib resistance EGFR recurrent mutation in EGFR-mutant lung cancer
T Dahal, BR Subedi